MedTrace Logo

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

NCT01609959 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2013-10-30

No results posted yet for this study

Summary

The purpose of this study is to compare blood pressure lowering effect of azilsartan with that of valsartan in Japanese patients with hypertension who have already taken normal-dose angiotensin II receptor blockers.

Conditions

Interventions

DRUG

Azilsartan

Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks

DRUG

Valsartan

Valsartan 160 mg per day

Sponsors & Collaborators

  • Nara Medical University

    lead OTHER

Principal Investigators

  • Yoshihiko Saito, MD, PhD · First Department of Internal Medicine, Nara Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-09-30
Completion
2013-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609959 on ClinicalTrials.gov